Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR(R) (niacinextended-release/simvastatin)

By Pharmaceutical Processing | December 10, 2009

Abbott has submitted a supplemental new drug application (sNDA) to the U.S. Food andDrug Administration (FDA) for two new dosage strengths of SIMCOR, acholesterol medication. SIMCOR is a fixed-dose combination of niacinextended-release and simvastatin. Abbott is seeking FDA approval for the following new dosage strengths ofSIMCOR: 500/40 mg and 1000/40 mg (niacin extended-release/simvastatin).SIMCOR was approved by the FDA in February 2008 in the following strengths:500/20 mg, 750/20 mg and 1000/20 mg. The original FDA approval was supportedby results from the SEACOAST trial, which demonstrated efficacy and safety ofSIMCOR up to doses of 2000/40 mg daily in patients with mixed dyslipidemia andtype II hyperlipidemia. SIMCOR is a prescription medicine used along with diet in people whocannot control their cholesterol levels by diet and exercise alone. SIMCOR isapproved to lower levels of elevated total cholesterol, LDL “bad” cholesteroland triglycerides, and to raise HDL “good” cholesterol. SIMCOR is used whentreatment with simvastatin alone or niacin extended-release alone is notconsidered adequate. No additional benefit of SIMCOR on heart disease overand above that shown for niacin alone and simvastatin alone has beendemonstrated. “If approved, availability of new SIMCOR dosage strengths would be goodnews for the many patients with complex lipid disease who need additionaloptions to treat their HDL, LDL and triglycerides,” said Eugene Sun, M.D.,vice president, Global Clinical Development, Abbott.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE